R:GEN

Macular laser for healthy RPE regeneration

Selectively targets RPE while preserving photoreceptors

Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients

R:GEN the only technology to facilitate RPE regeneration and improved retina function

Cleared Indications

FDA: Clinically Significant Macular Edema (CSME)
CE Mark: Central Serous Chorioretinopathy (CSC) & Diabetic Macular Edema (DME)
Korea - MFDS: Central Serous Chorioretinopathy (CSC) & Diabetic Macular Edema (DME)

CSC | DME

Chronic Central Serous Chorioretinopathy

R:GEN treatment targeting the peripheral area of leakage has shown favorable visual and structural outcomes in chronic CSC patients without causing scotoma.

RGEN CSC clinical

Resolution of SRF/PED and Safety of the Treatment

Change of best-correct visual acuity (BCVA) (logMAR) in R:GENtreated patients with chronic central serous chorioretinopathy (CSC). Error bars represent standard deviation (SD). The difference of BCVA (logMAR) was statistically significant at 2 and 3 months after SRT. *P<0.05.

Reference: Roh et al. Graefes Arch Clin Exp Ophthalmol (2016). DOI 10.1007/s00417-015-3262-1

Diabetic Macula Edama

R:GEN has been shown to be an effective and safe treatment of clinically significant DME, it shows functional and anatomical improvement or stabilization in 84% of patients.

Reduction of hard exudates and retinal thickness before and 6 months after the treatment

RGEN DME graph

Mean BCVA improved from 43.7 letters (standard deviation,

SD=9.1) at baseline to 46.1 letters (SD=10.5) at the 6-month

follow-up (p=0.02).

Reference: Roider J, Klatt C, Brinkmann R et al. Graefes Arch Clin Exp

Ophthalmol. 2010;248:1263-1272